GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Cyclically Adjusted PS Ratio

Anixa Biosciences (Anixa Biosciences) Cyclically Adjusted PS Ratio : (As of Jun. 09, 2024)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anixa Biosciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Anixa Biosciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Cyclically Adjusted PS Ratio Chart

Anixa Biosciences Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anixa Biosciences Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.07 - - - -

Competitive Comparison of Anixa Biosciences's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Anixa Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Cyclically Adjusted PS Ratio falls into.



Anixa Biosciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Anixa Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Apr. 2024 is calculated as:

For example, Anixa Biosciences's adjusted Revenue per Share data for the three months ended in Apr. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Apr. 2024 (Change)*Current CPI (Apr. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Apr. 2024) = 131.7762.

Anixa Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201407 0.102 100.520 0.134
201410 0.139 100.176 0.183
201501 0.899 98.604 1.201
201504 0.003 99.824 0.004
201507 0.010 100.691 0.013
201510 0.000 100.346 0.000
201601 0.000 99.957 0.000
201604 0.000 100.947 0.000
201607 0.011 101.524 0.014
201610 0.023 101.988 0.030
201701 0.000 102.456 0.000
201704 0.000 103.167 0.000
201707 0.025 103.278 0.032
201710 0.000 104.070 0.000
201801 0.000 104.578 0.000
201804 0.045 105.708 0.056
201807 0.020 106.324 0.025
201810 0.000 106.695 0.000
201901 0.000 106.200 0.000
201904 0.013 107.818 0.016
201907 0.000 108.250 0.000
201910 0.000 108.577 0.000
202001 0.000 108.841 0.000
202004 0.000 108.173 0.000
202007 0.000 109.318 0.000
202010 0.000 109.861 0.000
202101 0.020 110.364 0.024
202104 0.000 112.673 0.000
202107 0.000 115.183 0.000
202110 0.000 116.696 0.000
202201 0.000 118.619 0.000
202204 0.000 121.978 0.000
202207 0.000 125.002 0.000
202210 0.000 125.734 0.000
202301 0.000 126.223 0.000
202304 0.007 127.992 0.007
202307 0.000 128.974 0.000
202310 0.000 129.810 0.000
202401 0.000 130.124 0.000
202404 0.000 131.776 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anixa Biosciences  (NAS:ANIX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Anixa Biosciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences (Anixa Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747